secwatch.observer — SEC 8-K summary
======================================

Issuer:     Xenetic Biosciences, Inc. (XBIO)
CIK:        0001534525
Form:       8-K
Filed at:   2025-11-13T23:59:59+00:00
Accession:  0001683168-25-008288
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Xenetic Biosciences Q3 net loss ~$0.5M, revenue up 67% to $1.0M; cash extended by $3.9M offering
--------------------------------------------------------------------------------

- Net loss of approximately $0.5M for Q3 2025; revenue rose 67% YoY to $1.0M on higher Takeda royalty payments.
- R&D expenses increased 105.6% to $0.8M due to manufacturing and pre-clinical work; G&A rose 9.3% to $0.8M on legal costs.
- Cash at Sept 30, 2025 was ~$4.1M; subsequent October 2025 offering added ~$3.9M net proceeds, extending runway.
- DNase I program advancing toward IND submission and Phase 1 for pancreatic and solid tumors; preclinical studies ongoing.
- PeriNess agreement for investigator-initiated studies in Israeli centers under regulatory approval process.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1534525/000168316825008288/0001683168-25-008288-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1534525/000168316825008288/xenetic_8k.htm
  HTML page:      https://secwatch.observer/filing/0001683168-25-008288

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer